Extended Data Fig. 8: MYH10 deficiency phenocopies LIPTERKO in CMs.
From: Lipid droplet-associated lncRNA LIPTER preserves cardiac lipid metabolism
a, PCR detection of MYH10 null hiPSC clones confirms successful knockout of MYH10. b, Mitochondria stress assay results collected from a Seahorse XF96 Analyzer showing the differences of maximal oxygen consumption values with Palmitate:BSA between conditions without and with Etomoxir (Eto). The yellow zone in panels represent FAO capabilities of WT and MYH10KO hiPSC-CMs. c, Representative immunofluorescent images for TUNEL and cTnT co-staining in WT and MYH10 KO hiPSC-EB sections. d, Representative images showing LD accumulation and cytosolic distribution in WT and MYH10KO hiPSC-CMs treated with 200 μM palmitic acid for 6 h. The experiment was carried out 4 times with similar outcomes. d', Quantification of relative LD density in the 1/2 cytosolic areas of CMs in d. (n = 4 independent experiments). e, Quantification of fluorescence levels in mitochondria isolated from WT and MYH10KO hiPSC-CMs after Rhodamine B-palmitic acid treatment for 2 h. (n = 3 independent experiments). f, Representative images of Oil Red O lipid staining (first two columns); Nile Red and cTnT co-staining (3 rd column) in WT hiPSC-EBs treated with (S)-(-)-Blebbistatin or (R)-(-)-Blebbistatin for 10 days. g, Representative images of TUNEL and cTnT co-staining in WT hiPSC-EBs treated with (S)-(-)-Blebbistatin or (R)-(-)-Blebbistatin for 10 days. h, Quantification of TUNEL+ CM ratios in WT hiPSC-CMs treated with (S)-(-)-Blebbistatin or (R)-(-)-Blebbistatin for 10 days. (n = 5 independent experiments). i, Immunofluorescent images showing Myh10 deficiency in Myh10CKO mouse heart. In d', e, h, bars represent mean values ± s.e.m. Unpaired two-tailed t-test is used for comparison. ***p < 0.001, **p < 0.01, *p < 0.05. Source numerical data are available in source data.
